Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lomefloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | CLK2 | P49760 | 1/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lomefloxacin SCHEMBL34610 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL29895425 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL34609 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL9226104 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL29388501 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL8912235 | 0.99 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL30034879 | 0.99 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL42051 | 0.99 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL42052 | 0.99 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL2636428 | 0.99 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-3711797-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2025-02-12 | — | — | EP | claimed |
| EP-3508501-B1 | USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS | H LUNDBECK AS (DK) | 2024-11-06 | — | — | EP | claimed |
| EP-4434588-A2 | AEROSOL DELIVERY DEVICE AND METHOD OF OPERATING THE AEROSOL DELIVERY DEVICE | PARI Pharma GmbH (DE) | 2024-09-25 | — | — | EP | claimed |
| EP-3756665-B1 | INTERVAL THERAPY FOR THE TREATMENT OF EYE DISEASES | UNIV RAMOT (IL) | 2024-08-14 | — | — | EP | claimed |
| EP-3374391-B1 | ANTIBODY MOLECULE-DRUG CONJUGATES THAT SPECIFICALLY BINDS TO LIPOPOLYSACCHARIDE AND USES THEREOF | VISTERRA INC (US) | 2024-04-17 | — | — | EP | claimed |
| EP-3122757-B1 | CHARGED LINKERS AND THEIR USES FOR CONJUGATION | HANGZHOU DAC BIOTECH CO LTD (CN) | 2023-09-06 | — | — | EP | claimed |
| EP-3845253-B1 | SUSTAINED-RELEASE INJECTION PREPARATION CONTAINING CONJUGATE OF POLY-L-LACTIC ACID FILLER AND HYALURONIC ACID FILLER AND MANUFACTURING METHOD THEREFOR | GCS CO LTD (KR) | 2023-03-22 | — | — | EP | claimed |
| EP-3021832-B9 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-03-15 | — | — | EP | claimed |
| EP-1227856-A1 | INHALATION NEBULIZER | PARI GmbH Spezialisten für effektive Inhalation (DE) | 2002-08-07 | — | — | EP | claimed |
| WO-2001034232-A9 | INHALATION NEBULIZER | PARI GMBH (DE) | 2002-08-01 | — | — | WO | claimed |
| EP-0925308-B1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH INC (CA) | 2002-06-05 | — | — | EP | claimed |
| EP-1115405-A1 | USE OF CERTAIN DRUGS FOR TREATING NERVE ROOT INJURY | A+ Science Invest AB (SE) | 2001-07-18 | — | — | EP | claimed |
| WO-2001034232-A1 | INHALATION NEBULIZER | Pari GmbH Spezialisten für effektive Inhalation (DE) | 2001-05-17 | — | — | WO | claimed |
| EP-0661974-B1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION USING OPTICALLY PURE (R)-LOMEFLOXACIN | SEPRACOR INC (US) | 2000-09-06 | — | — | EP | claimed |
| WO-2000018409-A1 | USE OF CERTAIN DRUGS FOR TREATING NERVE ROOT INJURY | A+ SCIENCE INVEST AB (SE) | 2000-04-06 | — | — | WO | claimed |
| EP-0659763-B1 | 21-Hydroxy pregnane - Quinoline carboxylic acid esters and Antibacterial and Antiinflammatory compositions containing them | SENJU PHARMA CO (JP) | 1998-05-20 | — | — | EP | claimed |
| EP-0443381-B2 | Effervescent composition, its production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| EP-0394553-B1 | Use of fluorine containing pyridone carboxylic acid derivatives for preparing a medicament for the treatment of HIV infections | DAIICHI SEIYAKU CO (JP) | 1995-06-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | IL1B, IL5, SERPINB1 | KDM4E 4014/4885HSD17B10 3520/4885ALDH1A1 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.